Effects of antihypertensive treatment on cardiac IGF-1 during prevention of ventricular hypertrophy in the rat

Life Sciences

Volumn 64, Issue 18, 1999, Pages 1603-1612

  Jalil, Jorge E ^a,b   Ebensperger, Roberto ^a,b   Meléndez, Jaime ^a,b   Acevedo, Erika ^a,b   Sapag Hagar, Mario ^a,b   González Jara, Fabían ^a,b   Gálvez, Anita ^a,b   Pérez Montes, Viviana ^a,b   Lavandero, Sergio ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

methyldopa; Enalapril; Heart hypertrophy; Hypertension; Insulin like growth factor 1; Losartan; Propanolol

Indexed keywords

ANTIHYPERTENSIVE AGENT; ENALAPRIL; GROWTH HORMONE; LOSARTAN; METHYLDOPA; PROPRANOLOL; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HYPERTENSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENALAPRIL; HEART; HYPERTROPHY, LEFT VENTRICULAR; INSULIN-LIKE GROWTH FACTOR I; LOSARTAN; MALE; METHYLDOPA; MYOCARDIUM; PROPRANOLOL; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0033605841     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(99)00097-1     Document Type: Article

References (47)

1. H.E. Morgan and K.M. Baker, Circulation 83 13-25 (1991).
2. R.S Decker, M.L Decker, M. Behnke-Barclay, D.M. Janes, and W.A Clark, Ann. N.Y. Acad. Sci. 752 168-186 (1995).
3. L. Sacca and S. Fazzio, Nature Med. 2 29-31 (1996).
4. J. Diez and C. Laviades, J. Human Hypertens. 8 S21-S25 (1994).
5. C. Laviades, G. Mayor and J. Diez, Arch. Mal. Coeur Vaisseaux 84 1039-1041 (1994).
6. H. Wahlander, J. Isgaard, E. Jennishe and P. Friberg, Hypertension 19 :25-32 (1992).
7. T. J. Donohue, M.D. Dworkin, M.N. Lango, K. Fliegner, R.P. Lango, J.A. Benstein, W.R Slater and V.M. Catanese, Circulation 89 799-809 (1994).
8. M.C. Hanson, K.A. Fath, R.W. Alexander and P. Delafontaine, Am. J. Med. Sci. 306 69-74 (1993).
9. G.L. Engelman, K.D. Boehm, J.F. Haskell, P.A. Khairallah and J. Ilan, Mol. Cell. Endocrinol. 63 1-14 (1989).
10. R. Ebensperger, E. Acevedo, J. Meléndez, R. Corbalàn, M. Acevedo, M. Sapag-Hagar, J.E. Jalil, and S. Lavandero, Biochem. Biophys. Res. Commun. 243 20-24 (1998).
11. H. Ito, M., Hiroe, Y. Hirata, T. Motoyoshi, S. Adachi, S. Masayoshi, A. Koike, A. Nogami and F. Marumo, Circulation 87 1715-1721 (1993).
12. R. Foncea, M. Andersson, A. Ketterman, V. Blakesley, M. Sapag-Hagar, P.H. Sugden, D. Leroith and S. Lavandero, J. Biol. Chem. 272 19115-19124 (1997).
13. S. Lavandero, R. Foncea, V. Pérez and M. Sapag-Hagar, FEBS Lett. 422 193-196 (1998).
14. P. Delafontaine, Cardiovasc. Res. 30 825-834, (1995).
15. J. Díez, C. Laviades, E. Martínez, M.J. Gil, I. Monreal, J. Fernández, and J. Prieto J. Hypertens. 13 349-355 (1995).
16. A. Cittadini, H. Strömer, S.E. Hatz, R. Clark, A. Moses, J.P. Morgan, and P.S. Douglas, Circulation 93 800-809 (1996).
17. P. Delafontaine, M. Brink and J. Du, Trends Cardiovasc. Med. 6, 187-193 (1996).
18. M. Brink, J. Wellen, and P. Delafontaine, J. Clin. Invest. 97 2509-2516 (1996).
19. J. Diez, C. Laviades and G. Mayor, J. Human Hypertens. 7 479-484. (1993).
20. J. Diez and C. Laviades, J. Hypertens. 12 S31-S36 (1994).
21. T.J. Donohue, L.D. Dworkin, J. Ma, M.N. Lango and V.M. Catanese, J. Investig. Med. 45 584-591 (1997).
22. A. M. Piddo, I. Sánchez, M. Sapag-Hagar, R. Corbalán, I. Godoy, J.E. Jalil, and S. Lavandero, J. Mol. Cell. Cardiol. 28 1073-1083 (1996).
23. G. Dussaillant, H. Gonzalez, C. Cespedes and J.E. Jalil, J. Hypertension 14 1117-1123 (1996).
24. S. Lavandero, G. Cartagena, E. Guarda, R. Corbalán, I. Godoy, .M Sapag-Hagar and J.E. Jalil, Cardiovasc. Res. 27 1634-1638 (1993).
25. G. Dussaillant, H. González and J.E. Jalil, Rev. Chil. Cardiol. 15 172-178 (1996).
26. P.J. Fraker and J.C. Speck, Biochem. Biophys. Res. Commun. 80 849-852 (1978).
27. S. Lavandero, J.F. Santibañez, M.P. Ocaranza, A. Ferreira and M. Sapag-Hagar, Comp. Biochem. Physiol. 99A 507-511 (1991).
28. B.A. Crawford, J.L. Martin, C.J Howe, D.J.H. Handelsman and R.C. Baxter, J. Endocrinol. 134 169-176 (1992).
29. M. Huang, D.S. Friend, M.E. Sunday, K. Singh, K. Haley, K.F. Austen and R.A. Kelly, J. Clin. Invest. 98 1298-1303 (1996).
30. D.E. Dostal and K. M. Baker, Trends Cardiovasc. Med. 3 67-74 (1993).
31. V.J. Dzau, Am. J. Cardiol. 70 4C-11C (1992).
32. T. Yamazaki, Y. Komuro, R. Nagai and Y. Yazaki, Cardiovasc. Res. 31 493-498 (1996).
33. H. Yang, M. Anaqeeb, H. Simpson and G. Goldspink G, J. Anat. 190 613-622 (1997).
34. L. Mao, L. Pusl, J.J. Hunter, L PoweLL-Braxton, K.R. Chien and J. Ross, Circulation 92 I-239-240 (Abstract) (1996).
35. K.A. Fath, R.W. Alexander and P. Delafontaine, Circ. Res. 72 271-277 (1993).
36. R.L. Duerr, S. Huang, H.R. Miraliakbar, R Clark, K.R. Chien and J. Ross, J. Clin. Invest. 95 619-627 (1995).
37. M. Martinez-Maldonado, Hypertension 17 707-719 (1991).
38. R. Ebensperger, E. Acevedo, J. Meléndez, E. Ballcels, G. Cartagena, M. Sapag-Hagar, J.E. Jalil, C. Cespedes, C. Vio and S. Lavandero, Rev. Chil. Cardiol. 14 63-68 (1995).
39. J.I. Jones and D.R. Clemmons, Endocrine Rev. 16 3-34 (1995).
40. A. Anwar and P. Delafontaine, Hypertension 24 679-685 (1994).
41. P. Delafontaine and H. Lou, J. Biol Chem. 268 16866-16870 (1993).
42. B. Noel, G. Del Re, P. Capone, H.R. Brunner and J Nussberger, J. Cardiovasc. Pharmacol. 28 252-258 (1996)
43. K. Mizumo, S. Niimura, K. Katoh and S. Fukuchi, Life Sci. 54 1987-1994 (1994)
44. S.N. Iyer, M.C. Chappel, K.B. Brosnihan and C.M. Ferrario, J. Cardiovac. Pharmacol. 31 464-469 (1998)
45. C.S. Long, W.E. Hartogensis and P.C. Simpson, J. Mol. Cell. Cardiol. 25 915-925 (1993)
46. P. C. Simpson, J. Clin. Invest. 72 732-738 (1983).
47. Z.W. Hu, X.Y. Shi and B.B. Hoffman, J. Clin. Invest. 98 1826-1834 (1996).